Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) has issued an update.
Alphamab Oncology announced that its drug JSKN003, co-developed with Shanghai JMT-Bio Technology, has been granted breakthrough therapy designation by the CDE for treating HER2+ advanced colorectal cancer (CRC) in patients who have failed prior treatments. This designation highlights the significant unmet clinical need in China, where CRC is highly prevalent, and no HER2-targeted therapies are currently approved. Preliminary results from clinical trials show JSKN003’s notable efficacy and favorable safety profile, potentially positioning it as a promising treatment option for HER2-overexpressing CRC patients.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in the PRC, specializing in the development of antibody-based therapies for oncology. The company has a fully integrated proprietary technology platform focusing on ADCs, bispecific antibodies, and multi-functional protein engineering. Its pipeline includes products in various stages of development, with one product already approved for marketing by the NMPA.
Average Trading Volume: 4,202,481
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.02B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.